000095772 001__ 95772
000095772 005__ 20231006143300.0
000095772 0247_ $$2doi$$a10.3390/biomedicines8090328
000095772 0248_ $$2sideral$$a120209
000095772 037__ $$aART-2020-120209
000095772 041__ $$aeng
000095772 100__ $$aBernal-Monterde, V.
000095772 245__ $$aSARS-CoV-2 infection induces a dual response in liver function tests: Association with mortality during hospitalization
000095772 260__ $$c2020
000095772 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095772 5203_ $$aSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with abnormal liver function tests. We hypothesized that early altered liver biochemistries at admission might have different clinical relevance than subsequent changes during hospitalization. A single-center retrospective study was conducted on 540 consecutive hospitalized patients, PCR-diagnosed with SARS-CoV-2. Liver test abnormalities were defined as the elevation of either gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST), above the upper limit of normality set by our laboratory. Linear mixed models (LMM) evaluated longitudinal associations, incorporating all available follow-up laboratory chemistries. By the end of the follow-up period, 502 patients (94.5%) were discharged (109 (20.5%) died). A total of 319 (64.3%) had at least one abnormal liver test result at admission. More prevalent were elevated AST (40.9%) and GGT (47.3%). Abnormalities were not associated with survival but with respiratory complications at admission. Conversely, LMM models adjusted for age and sex showed that longitudinal increases during hospitalization in ferritin, GGT, and alkaline phosphatase (ALP), as well as a decreased albumin levels, were associated with reduced survival. This dual pattern of liver damage might reconcile previous conflicting reports. GGT and ALP trajectories could be useful to determine who might need more surveillance and intensive care.
000095772 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B03-20R$$9info:eu-repo/grantAgreement/ES/DGA-FEDER/Construyendo Europa desde Aragón$$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-02268
000095772 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095772 590__ $$a6.081$$b2020
000095772 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b65 / 296 = 0.22$$c2020$$dQ1$$eT1
000095772 591__ $$aPHARMACOLOGY & PHARMACY$$b33 / 275 = 0.12$$c2020$$dQ1$$eT1
000095772 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b32 / 140 = 0.229$$c2020$$dQ1$$eT1
000095772 592__ $$a1.51$$b2020
000095772 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000095772 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2020$$dQ1
000095772 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095772 700__ $$0(orcid)0000-0001-6883-8940$$aCasas-Deza, D.
000095772 700__ $$aLetona-Giménez, L.
000095772 700__ $$aLlama-Celis, N.
000095772 700__ $$aCalmarza, P.
000095772 700__ $$aSierra-Gabarda, O.
000095772 700__ $$aBetoré-Glaria, E.
000095772 700__ $$aMartínez-de-Lagos, M.
000095772 700__ $$aMartínez-Barredo, L.
000095772 700__ $$aEspinosa-Pérez, M.
000095772 700__ $$0(orcid)0000-0002-8982-3737$$aArbones-Mainar, J.M.
000095772 773__ $$g8, 9 (2020), 328 [12 pp]$$tBiomedicines$$x2227-9059
000095772 8564_ $$s483873$$uhttps://zaguan.unizar.es/record/95772/files/texto_completo.pdf$$yVersión publicada
000095772 8564_ $$s447936$$uhttps://zaguan.unizar.es/record/95772/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095772 909CO $$ooai:zaguan.unizar.es:95772$$particulos$$pdriver
000095772 951__ $$a2023-10-06-14:06:44
000095772 980__ $$aARTICLE